2022 cancer statistics: Focus on lung cancer.

IF 3 4区 医学 Q2 ONCOLOGY Future oncology Pub Date : 2024-06-05 DOI:10.2217/fon-2022-1214
Rachel Jenkins, Joanne Walker, Upal Basu Roy
{"title":"2022 cancer statistics: Focus on lung cancer.","authors":"Rachel Jenkins, Joanne Walker, Upal Basu Roy","doi":"10.2217/fon-2022-1214","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fon-2022-1214","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2022 年癌症统计数据:关注肺癌。
这个总结是关于什么的?这是一篇题为《2022年癌症统计》的医学期刊文章的简明扼要的摘要。这份摘要中的数据提供了关于肺癌的详细信息,而关于其他癌症的信息则不太详细。原始研究的研究人员利用前几年收集的数据进行了癌症预测,预测了2022年美国新癌症诊断和死亡人数。结果如何?对截至2019年的数据的审查发现,与前几年相比:晚期肺癌诊断率下降,局部肺癌诊断率上升,肺癌死亡率下降,乳腺癌死亡率继续下降,但女性乳腺癌的诊断率每年都在缓慢上升,前列腺癌的诊断率保持不变,局部前列腺癌的诊断率保持不变,晚期前列腺癌的诊断率每年都在增加。研究人员估计,到2022年,美国将有超过190万例新的癌症病例被诊断出来,超过50万例癌症死亡。这一数字包括每天约350人死于肺癌,肺癌被发现是美国癌症死亡的主要原因。这项研究的结果意味着什么?当前位置研究发现,在减少乳腺癌和前列腺癌确诊人数方面的进展已经停滞。虽然肺癌确诊病例减少了,但这种减少可能是由于筛查的变化和肺癌治疗的进步造成的。美国癌症协会(American Cancer Society)建议,在早期发现癌症和开发有针对性的治疗方法方面投入更多资金,将有助于降低癌症死亡率。这也将有助于解决基于种族、社会和经济不平等而存在的在获得癌症治疗方面的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Future oncology
Future oncology ONCOLOGY-
CiteScore
5.40
自引率
3.00%
发文量
335
审稿时长
4-8 weeks
期刊介绍: Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
期刊最新文献
Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer. Artificial intelligence and radiomics in desmoid-type fibromatosis: are we there yet? Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer. Tislelizumab for consolidation therapy in patients with pathologically residual Esophageal Squamous Cell Carcinoma after definitive concurrent Chemoradiotherapy: a multicenter, randomized, controlled phase II trial. Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1